Literature DB >> 20686436

Timing of the availability and administration of influenza vaccine through the vaccines for children program.

Praful Bhatt1, Stan L Block, Seth L Toback, Christopher S Ambrose.   

Abstract

BACKGROUND: influenza vaccine must be distributed and administered each year during a limited time interval. To our knowledge, no previous studies have simultaneously evaluated the delivery and administration of privately purchased vaccines and influenza vaccines acquired through the Vaccines for Children (VFC) program.
METHODS: a prospective, observational study was conducted in US outpatient pediatric offices, tracking all influenza vaccinations during the season by age group, first or second vaccination, the child's need for 1 or 2 doses, type of vaccine, and VFC status.
RESULTS: a total of 42 and 84 practices completed the study in 2007 to 2008 and 2008 to 2009, respectively. In both seasons, initial shipments of VFC influenza vaccine generally arrived 4 to 5 weeks later than non-VFC shipments; VFC vaccine administration also started 1 month later than administration of privately purchased vaccine. Vaccine administration peaked in early November and late October in years 1 and 2, respectively, and declined rapidly thereafter. Overall, approximately one-half of all children who required 2 doses of vaccine were estimated to have received 2 doses. In both years, 2-dose compliance rates in the VFC population were 17% to 19% lower than those in the non-VFC population, possibly resulting from the VFC population's shorter time interval for second dose receipt.
CONCLUSIONS: the VFC program is critical to ensuring financially vulnerable children have access to vaccination. Manufacturers, distributors, and public health officials should deliver VFC influenza vaccine to providers as quickly as possible. Pediatric healthcare providers should increase efforts to vaccinate all populations, especially the VFC population, in later months.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20686436     DOI: 10.1097/INF.0b013e3181efff54

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  7 in total

1.  Timeliness of pediatric influenza vaccination compared with seasonal influenza activity in an urban community, 2004-2008.

Authors:  Annika M Hofstetter; Karthik Natarajan; Daniel Rabinowitz; Raquel Andres Martinez; David Vawdrey; Stephen Arpadi; Melissa S Stockwell
Journal:  Am J Public Health       Date:  2013-05-16       Impact factor: 9.308

2.  Parental-Reported Full Influenza Vaccination Coverage of Children in the U.S.

Authors:  Yusheng Zhai; Tammy A Santibanez; Katherine E Kahn; Anup Srivastav
Journal:  Am J Prev Med       Date:  2016-12-21       Impact factor: 5.043

Review 3.  Influenza vaccines for preventing acute otitis media in infants and children.

Authors:  Mohd N Norhayati; Jacqueline J Ho; Mohd Y Azman
Journal:  Cochrane Database Syst Rev       Date:  2017-10-17

4.  Cluster randomized trial of a toolkit and early vaccine delivery to improve childhood influenza vaccination rates in primary care.

Authors:  Richard K Zimmerman; Mary Patricia Nowalk; Chyongchiou Jeng Lin; Kristin Hannibal; Krissy K Moehling; Hsin-Hui Huang; Annamore Matambanadzo; Judith Troy; Norma J Allred; Greg Gallik; Evelyn C Reis
Journal:  Vaccine       Date:  2014-04-29       Impact factor: 3.641

5.  Text message reminders for second dose of influenza vaccine: a randomized controlled trial.

Authors:  Melissa S Stockwell; Annika M Hofstetter; Nathalie DuRivage; Angela Barrett; Nadira Fernandez; Celibell Y Vargas; Stewin Camargo
Journal:  Pediatrics       Date:  2015-01       Impact factor: 7.124

6.  Factors impacting influenza vaccination of urban low-income Latino children under nine years requiring two doses in the 2010-2011 season.

Authors:  Annika M Hofstetter; Angela Barrett; Melissa S Stockwell
Journal:  J Community Health       Date:  2015-04

Review 7.  Prevention of influenza in healthy children.

Authors:  Bruce Y Lee; Mirat Shah
Journal:  Expert Rev Anti Infect Ther       Date:  2012-10       Impact factor: 5.091

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.